Will the Phase 2 trial "Doravirine/Lamivudine (DOR/3TC) as a Maintenance ART in Comparison With Dolutegravir/Lamivudine (DTG/3TC) in PLWH Successfully" reach primary completion on or before Jan 15, 2027?

Resolves Yes if ClinicalTrials.gov record NCT06774872 (Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida) shows an actual primary completion date on or before Jan 15, 2027. Registered date at generation: Jan 15, 2027.

Outcome verified from clinicaltrials.gov.

1. Market open

   Jul 17, 2026, 7:40 AM UTC
2. Market closes

   By Jan 15, 2027, 11:59 PM UTC
3. Projected payout

   Shortly after the market closes

Trading on material non-public information is prohibited. Markets are for entertainment and informational purposes using free Pulse Credits — no real-money wagering. If you believe a participant has acted on inside information, please report it.